论文部分内容阅读
作者将伤寒杆菌Vi荚膜多糖分别与大肠杆菌不耐热肠毒素B亚单位（LT-B）和重组绿脓杆菌外蛋白A（rEPA）制成结合菌苗免疫动物和人体,观察其免疫原性及安全性。 用5μgVi多糖菌苗和相当于该剂量的Vi-LT-B、Vi-rEPA免疫小鼠和豚鼠,分别于第0、14和21天和第0、21和42天注射,第7、21、28天和第 0、21、42、64天取血清Vi抗体用放射免疫法（RIA）检测。普通小鼠注射第1针后测得Vi抗体水平为Vi组1.37μg/ml、Vi-LT-B组 6.26μg/ml、Vi-rEPA组8.82μg/ml,后两组与Vi组相比差异非常显著。第2针只注射了Vi-LT-B组和Vi-rEPA
The authors inoculated Salmonella typhi Vi capsular polysaccharide with E. coli heat-labile enterotoxin B subunit (LT-B) and recombinant Pseudomonas aeruginosa exoprotein A (rEPA) Sexuality and safety. The mice were immunized with 5 μg of Vi polysaccharide vaccine and Vi-LT-B, Vi-rEPA and guinea pigs at this dose on days 0, 14 and 21, and days 0, 21 and 42, respectively, Serum Vi antibody was detected by radioimmunoassay (RIA) on days 28, 0, 21, 42 and 64. The level of Vi antibody in normal mice was 1.37μg / ml in Vi group, 6.26μg / ml in Vi-LT-B group and 8.82μg / ml in Vi-rEPA group after 1 st injection. The difference between the latter two groups and Vi group Very significant. The second needle was injected with Vi-LT-B and Vi-rEPA only